Thakker has published 169 papers and book chapters, co-edited two books, delivered 185 invited lectures, and is an inventor on several patents.Thakker served as a Co-Editor of Medicinal Research Reviews and served on the editorial boards of several scientific journals and on scientific advisory boards of several biotech companies. Thakker co-founded a university startup company, Qualyst, Inc., Analytical Solutions, Inc., Tergus Pharma, and Sphaera Pharma. He has served on the Board of Qualyst, Tergus Pharma, and Sphaera Pharma USA, and is on the Board of MBF Therapeutics and Med Aditus International. He is a recipient of the Sato Memorial Award from the Pharmaceutical Society of Japan, Distinguished Alumnus Award from the Institute for Chemical Technology, Bombay University, and is a Fellow of the American Association of Pharmaceutical Scientists.
After spending over four decades across the largest biomedical research institute in the world, the leading regulatory agency, a global pharmaceutical company, and the nation’s top ranked pharmacy school (UNC Eshelman School of Pharmacy), Thakker decided to spend the next phase of his life serving underserved patients in sub-Saharan Africa and improving their access to affordable, high-quality medicines.
In December 2019, he founded Med Aditus International, a nonprofit organization whose mission is to establish a manufacturing entity for much needed medicines, train the workforce and to mobilize talented individuals with a passion for service.
Paul W. Maffuid, Ph.D., serves as the Chief Scientific Officer of Med Aditus Pharmaceuticals, Inc. (MAP).
Maffuid has more than 35 years of drug discovery and development leadership experience including small molecule, peptide, and protein therapeutics. He established company infrastructures for transitioning programs from discovery into successful clinical development. His oversight in pharmacology, drug metabolism, drug safety evaluation, process chemistry, formulation development, analytical development, drug characterization, drug substance manufacturing, drug product manufacturing, clinical development and regulatory resulted in significant commercial value including acquisitions and licensing deals.
Maffuid created company processes to speed translation of discovery candidates by establishing regulatory discussions of program safety, pharmacology, and chemistry attributes prior to application.
Maffuid also has experience in exploiting new approaches to design and build cGMP pharmaceutical manufacturing and testing facilities, which included modular facility for the manufacture of drug substance, parenteral and oral drug products, and open format analytical laboratories for efficient testing of products.
Prior to joining MAP in 2023, Maffuid served as President at Biopharmalogics and as Chief Data Officer at Aayam Therapeutica. He was CEO of Sphaera Pharma and served as Executive Vice President at MabVax Therapeutics and at
AAI Pharma.
He received a Bachelor of Science from St. Michael’s College, VT, a Master of Science and a Ph.D. in Organic Chemistry from the University of California, San Diego.
Nazeem Mohamed has over 45 years of experience in the global pharmaceutical sector with a strong focus on Africa. He is currently the Pharmaceutical Specialist for the African Development Bank (AfDB). He also advises different organizations as an International Pharmaceutical Consultant.
He serves as Lead Pharmaceutical Consultant for UNIDO (Vienna), driving several projects to support local manufacturing in Africa; Lead Consultant for UNCTAD (Geneva) in Uganda on “Investment framework for local production of antibiotics in light of mitigating anti-microbial resistance;” GIZ representative on the AU-CDC Partnership for African Vaccine Manufacturing (PAVM) project which developed a road map for a sustainable vaccine industry in Africa; Consultant with Unizima (Belgium) on developing a financial model for a sustainable vaccine manufacturing facility in Africa, and Consultant on a AUDA project on selection of 24 products for manufacturing in Africa.
© Med Aditus Pharmaceuticals 2024
